Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

Analysts at Truist Securities called J&J’s CAR-T readout “compelling,” noting that the efficacy figures could position the ...

According to an internal email, the agency may be in for more consolidation in areas including human resources, ...

Sarepta’s shares crashed 41% in pre-market trading Monday morning to $21.01 after the biotech reported a second death from ...

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...

BIO International Convention (BIO2025), the world’s largest annual biotech event, will take place from June 16 to 19 (U.S.

While cancelled NIH grants and regulatory uncertainty are less hospitable to clinical research in the U.S., Europe must play ...

Martin Kulldorff and Robert Malone, both outspoken vaccine skeptics, have received compensation for their expert ...

The FDA’s Oncologic Drugs Advisory Committee narrowly voted against the approval of Zusduri, citing the lack of a completely ...

The American Medical Association is also urging an “immediate reversal” of the HHS Secretary's decision to oust all 17 ...

Gene therapies have ridden investor mania to huge valuations but commercialization challenges have pushed market caps to the ...